anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Type 2 Diabetes (T2D) is influenced by genetic, environmental, and ageing factors. Ageing pathways exacerbate metabolic diseases. This study aimed to examine both clinical and genetic factors of T2D in older adults.
METHODS: A total of 2,909 genotyped patients were enrolled in this study. Genome Wide Association Study was conducted, comparing T2D patients to non-diabetic older adults aged ≥ 60, ≥ 65, or ≥ 70 years, respectively. Binomial logistic regressions were applied to examine the association between T2D and various risk factors. Stepwise logistic regression was conducted to explore the impact of low HDL (HDL < 40 mg/dl) on the relationship between the genetic variants and T2D. A further validation step using data from the UK Biobank with 53,779 subjects was performed.
RESULTS: The association of T2D with both low HDL and family history of T2D increased with the age of control groups. T2D susceptibility variants (rs7756992, rs4712523 and rs10946403) were associated with T2D, more significantly with increased age of the control group. These variants had stronger effects on T2D risk when combined with low HDL cholesterol levels, especially in older control groups.
CONCLUSIONS: The findings highlight a critical role of age, genetic predisposition, and HDL levels in T2D risk. The findings suggest that individuals over 70 years who have high HDL levels without the T2D susceptibility alleles may be at the lowest risk of developing T2D. These insights can inform tailored preventive strategies for older adults, enhancing personalized T2D risk assessments and interventions.
The present disclosure is related to the purification of quercetin glycosides from Larrea tridentata leaves using water, ethanol, and a stripping resin. Water acts as an extracting agent and ethanol allows the recovery of bioactive compounds after performing a resin-filled column liquid chromatography. The process begins with the dehydration and grinding of the leaves of governor at room temperature for a period of 10 days, then the extraction is carried out in a mass/volume ratio of 1:5 (1 part of dehydrated and ground material for 5 parts of water) at a temperature of 60°C for 30 minutes, the extract is filtered to obtain the aqueous part. A column is packed with the resin and unwanted compounds are removed. Subsequently, a second elution is carried out with ethanol to recover the fraction of bioactive compounds separated thanks to the interaction with the resin. Subsequently, the residual ethanol is evaporated at a temperature of 60°C to recover a fine powder. This obtained powder is purified by polarity separation using polar solvents (ethyl acetate, ethanol and methanol) and non-polar solvents (hexane and chloroform). To corroborate the separation of compounds, thin layer chromatography was performed with hexane as the mobile phase and characterized by FTIR spectroscopy. Finally, the polar extract was characterized by mass spectrometry and quercetin glycosides were identified.
The use of dynamic pelvic MRI has greatly impacted our preoperative evaluation of pelvic floor disorders, both anatomically and functionally. The STARR procedure is a new approved procedure for patients with obstructive defecation, who have failed conservative therapy of medications and aggressive pelvic floor retraining. Most patients have also been screened for colonic transit problems. The traditional study for evaluating these patients was defecating proctograms. With the advent of the dynamic pelvic MRI, we are now beginning to understand the interaction of the entire pelvic structure in the complex act of defecation. This study is providing us a different view of the pelvic structures to better understand the pathophysiology of this disorder. The defecating proctogram, though informative in certain cases, lacks information outside the rectum. We wish to evaluate and compare our preoperative dynamic pelvic MRI with a six month dynamic pelvic MRI in 10 patients. We also will compare pre and post op obstructive defecation scores (ODS). We expect this small sample to direct us to a much more pointed evaluation of this disorder.
The invention discloses a sticky strap for treating acute mastitis. The sticky strap comprises a sticky strap body (1). The four edges of the sticky strap body (1) are each provided with a set of intermittent sticky strips (4). A cataplasm (2) for sticking medicine is arranged on the cloth face of the sticky strip body (1). The four edges of the cataplasm (2) are each provided with a piece of preset paper (3) for containing medicine mud blocks conveniently. Frame strips of the cataplasm with no preset paper (3) can be used for being stuck to skin, wherein a medicine mud block formed by mashing goodyera repens, Moghania fluminalis, viola diffusa, scutellaria indica, Hedera nepalensis, Pellionia scabra Benth and PolygonumorientaleLinn on the basis of the ratio being 3:3:2:2:2:2:1 is arranged on the cataplasm (2). In implementation, the medicine mud block is prevented from being dry or heated through leaves of Japanese bananas, and the medicine effect is improved through white spirit; the effect of preventing irritability of the adhesion position can be achieved through the preset paper (3) and the intermittent sticky strips (4) on the sticky strap body (1). The sticky strap has the advantages of being proper in external application sticking, low in manufacturing cost, rapid in using effect and good in treatment effect.
Syringes and methods of preparing a stabilized hydrogen peroxide solution are described. A method includes filling a portion of a syringe with a hydrogen peroxide solution. The portion of the syringe may contact the hydrogen peroxide solution. The portion may be or include cycloolefin polymer (COP) or cycloolefin copolymer (COC). The method also includes storing the hydrogen peroxide solution in the syringe for a period of time. The hydrogen peroxide solution may be characterized by improved stability after the period of time relative to storing the hydrogen peroxide solution in a glass syringe for the period of time.
PURPOSE: To provide a compd. which consists of a xanthine deriv. having action to suppress the activation of the lymphocytes of mammals and is useful as a treatment medicine for a autoimmune disease. CONSTITUTION: The 7-(oxoalkyl)1,3-dialkylxanthine exclusive of the Denbufylline of the formula (R<1> , R<2> are a 2 to 6C alkyl, cyclohexyl, alkoxyalkyl, hydroxyalkyl; A is a 1 to 4C hydrocarbon which may be substd. with methyl) is used for producing a lymphocyte activation suppressor. The compd. suppress the activation of >=1 kinds of the lymphocytes selected from T helper cells, T cell damaging cell T suppressor cells, natural killer cells, killer cells which are the cause for cell damaging characteristics by interemediation of antibody dependent cells, T delay type irritable cells, B lymphocytes and groups consisting of the respective partial aggregates of these cell types.
Each subject will be placed in a comfortable position in a temperature regulated room. Participants will have two consecutive non invasive (NBM) measurements taken which involves inserting the thumb into a ring shaped sensor. After each non invasive measurement the sensor will be removed. Each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the Hb values. The two non invasive measurements will be performed using the same finger. After the NBM system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated complete blood count or Hb blood analyzers.
Part C is an adaptive style where the dosing level is a single- or multiple-ascending dose design. Based on safety and pharmacokinetic data from Parts A and B, doses for Part C will be chosen. Part C will be comprised of up to 50 participants over 5 cohorts of 10. Each participant will receive an oral dose of TLC-2716 or placebo at different dose levels (1 cohort per dose level).
Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
This is a Phase 1, dose escalation study of EC0489 administered by intravenous bolus (IV) during weeks 1 and 3 of a 4-week cycle in PART A and weekly on a 4-week cycle in PART B.

Both Parts are open to patients with refractory or metastatic cancer who have exhausted standard therapeutic options. EC0489 is a drug that is specifically designed to enter cells via a folate vitamin receptor. Experimental evidence shows that the target receptor is over-expressed in many human cancers. There are no previous human studies of EC0489; however, lab research (research in test tubes or animals) using EC0489 has shown activity against tumors in animals. This activity in animal models suggests that EC0489 may be useful as chemotherapy against human cancers. The primary objective of this study is to determine the safety and maximum tolerated dose of EC0489 given by intravenous bolus. The efficacy of treatment will also be measured.
PURPOSE: In Japan, gastrectomy with D2 lymph node dissection and postoperative adjuvant chemotherapy are the standard treatments for locally advanced gastric cancer. Neoadjuvant chemotherapy (NAC) is not affected by postgastrectomy syndromes or postoperative complications. This multicenter retrospective study investigated the prognostic factors and significance of postoperative adjuvant chemotherapy in patients with advanced gastric cancer who underwent NAC followed by gastrectomy.
METHODS: Consecutive patients (n = 221) with advanced gastric cancer who underwent NAC followed by curative surgery were enrolled in this study. Prognostic factors including postoperative adjuvant chemotherapy were investigated using univariate and multivariate analyses.
RESULTS: A multivariate analysis revealed that pathological lymph node metastasis (ypN) status and postoperative adjuvant chemotherapy were independent prognostic factors for the overall and relapse-free survival. Forty-five patients (20.4%) did not receive postoperative adjuvant chemotherapy. There were no significant differences between patients with and without adjuvant chemotherapy for all factors, except age. The most common reason for not undergoing postoperative adjuvant chemotherapy was a poor condition (n = 23).
CONCLUSIONS: ypN status and postoperative adjuvant chemotherapy were independent prognostic factors in gastric cancer patients who underwent NAC followed by curative gastrectomy. It is important to maintain the patient's condition during NAC and the perioperative period so that they can receive postoperative adjuvant chemotherapy.
Neuromuscular training exercises focus on improving physical fitness and skills performance. Neuromuscular training targets the neuromuscular system through engagements of muscle groups as well as nerve function to optimize movements. This training has been considered an effective treatment method to enhance the neurophysiological entity of the joints for coordinated functioning. However, the present study applied neuromuscular training to elite male handball players to assess fitness level as well as skill performance. Post-test 1 will be after 6 weeks, and post-test 2 after 12 weeks to measure performance.
Reproduction studies in the mouse and rabbit at doses up to 50 times the human dose showed no evidence of external abnormalities of the fetus due to EDECRIN.

In a two-litter study in the dog and rat, oral doses of 5 or 20 mg/kg/day (2½ or 10 times the human dose), respectively, did not interfere with pregnancy or with growth and development of the pups. Although there was reduction in the mean body weights of the fetuses in a teratogenic study in the rat at a dose level of 100 mg/kg (50 times the human dose), there was no effect on mortality or postnatal development. Functional and morphologic abnormalities were not observed.

There are, however, no adequate and well-controlled studies in pregnant women. Since animal reproduction studies are not always predictive of human response, EDECRIN should be used during pregnancy only if clearly needed.
One placebo tablet once daily for a duration of 48 weeks. Placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
FOCUS-EC is a trauma-informed, family-level, skill building program that provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping (including emotional regulation, problem solving, goal setting, communication, and management of trauma \& loss reminders), which foster parent-child and family cohesion. It is delivered in approximately 8 weekly sessions (including approximately six 60-minute sessions with parent/caregivers only, and two 30-60 minute sessions with children and parent/caregivers together). Each session is structured with a check-in, review of the previous week's "home activity," new skills-based activity and discussion, selection of a new "home activity," and a closing check-out. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family timeline and 2) enhancing parent-child interactions.
PURPOSE:To enable the essaying of diisopropylaminedichloroacetate (DADA) quickly at a high accuracy, by extracting a nitroso compound generated in the reaction between a sample containing DADA and NaNO2 under an acid condition to apply the extraction liquid to a chromatograph. CONSTITUTION:An NaNO2 aqueous solution is added to an acid aqueous solution of a sample of serum containing DADA having liver strengthening and detoxifying action or the like to react at 60 deg.C for about 10min. Then, the solution is iced and neutralized by a KOH aqueous solution. After the addition of NaCl, hexane is added to the solution, the mixture is stirred up thoroughly and undergoes a centrifugal separation. A fixed amount of a supernatant hexane solution is sampled, benzyl alcohol is added thereto and then the solution adjusted to a fixed capacity correctly by hexane is applied to a normal-phase chromatograph. Or it is subjected to a opposite-phase chromatograph using neutral or polar elution liquid. A quick and highly accurate quantitative analysis of DADA in a DADA medicine or the like can be done by use of a calibration curve obtained based on a known amount of DADA.
In the event of fluid overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.

In the event of overdosage with potassium-containing solutions, discontinue the infusion immediately and institute corrective therapy to reduce serum potassium levels.

Treatment of hyperkalemia includes the following:

  1. Dextrose Injection USP, 10% or 25%, containing 10 units of crystalline insulin per 20 grams of dextrose administered intravenously, 300 to 500 mL per hour. 
  2. Absorption and exchange of potassium using sodium or ammonium cycle cation exchange resin, orally and as retention enema. 
  3. Hemodialysis and peritoneal dialysis. The use of potassium-containing foods or medications must be eliminated. However, in cases of digitalization, too rapid a lowering of plasma potassium concentration can cause digitalis toxicity.
INTRODUCTION: To explore PTEN-induced putative kinase 1 (PINK1) expression and its clinical value in diabetic nephropathy.
METHODS: Ninety patients with diabetic nephropathy were recruited and divided into metformin hydrochloride monotherapy group, telmisartan monotherapy group and combination therapy (metformin and telmisartan) group. Renal function indices and PINK1 expression, inflammatory factors, reactive oxygen species (ROS), mitochondrial membrane potential (MMP) levels were detected. The correlation between PINK1 and inflammatory factors, renal function indicators including estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR) and serum creatinine (SCr)] were analyzed by Pearson correlation.
RESULTS: Following treatments, the combination therapy group exhibited increased PINK1 expression levels and decreased ROS levels compared to the groups receiving metformin hydrochloride or telmisartan monotherapy. The combination therapy group showed significant improvements in renal function indices and inflammatory markers. Additionally, the MMP ratio in the combination therapy group was higher compared to the two monotherapy groups. Furthermore, PINK1 was negatively correlated with UACR, SCr, tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), while positively correlated with eGFR and interleukin-2 (IL-2).
CONCLUSION: PINK1 exhibits low expression levels in patients with diabetic nephropathy and its expression is strongly associated with the inhibition of disease progression, thereby offering significant clinical diagnostic value. Additionally, it may serve as a potential biological marker for clinical diagnosis and treatment of diabetic nephropathy.
Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
BACKGROUND: Ablation of accessory pathways (APs) is the cornerstone for treatment of patients with Wolff-Parkinson-White syndrome and manifestation of atrioventricular reentrant tachycardia. Pulsed field ablation (PFA) is a new type of nonthermal energy source delivered to the underlying tissue via the ablation catheter and used for ablation of arrhythmic substrates.
OBJECTIVE: The purpose of this study was to determine the efficiency and long-term outcome of ablation of APs of different localizations using a focal pulsed electrical field.
METHODS: Electrophysiological study was performed in patients with indication for AP ablation. An ablation catheter was used to map the position of AP insertion. Pulsed electric field was delivered through a standard ablation catheter. In left-sided APs, the first ablation attempt was within the coronary sinus (CS). Patient follow-up was scheduled 1-3 months after the ablation. Additional check-up was performed after 6 and 12 months.
RESULTS: Fourteen 14 patients (3 pediatric) were treated. Termination of AP conduction was achieved in all procedures. The cohort consisted of 3 right free wall, 3 posteroseptal, and 8 left-sided APs. Ablation through CS was successfully used in 7 of 8 patients with left-sided APs. No complications were reported. Median follow-up was 5.5 months. Conduction recurrence through AP was documented in 1 patient.
CONCLUSION: Focal PFA for AP shows promising results in terms of efficacy and safety. A high rate of successful termination of left-sided APs by ablation within CS may represent a new standard approach. The safety and efficacy profile of PFA seems to be transferable to the pediatric population.
Narcissin is a natural flavonoid from some edible and traditional medicinal plants. It has been proven to have multiple biological functions and exhibits potential therapeutic effects on hypertension, cancer, and Alzheimer's disease. However, the toxicity of narcissin is largely unknown. Here, we revealed that narcissin treatment led to reduced hatchability, increased malformation rate, shorter body length, and slowed blood flow in zebrafish. Furthermore, bradycardia, pericardial edema, increased SV-BA distance, diminished stroke volume, ejection fraction, and ventricular short-axis shortening rate were also found. A large accumulation of ROS, increased apoptotic cells, and histopathological changes were detected in the heart region. Moreover, the gene expression profiles and molecular docking analysis indicated that Nrf2/HO-1 and calcium signaling pathways were involved in narcissin-induced toxicity. In conclusion, here we provide the first evidence that demonstrates narcissin-induced developmental toxicity and cardiotoxicity in zebrafish via Nrf2/HO-1 and calcium signaling pathways for the first time.
PURPOSE: Pseudomonas genus antibacterial microorganisms of pseudomonas tolaasii are provided to show superior antibacterial effect in respect to the brown blotch diseases of the mushrooms. CONSTITUTION: Antibacterial microorganisms comprise the basic sequence of a sequence number 1, KACC91694. The culturing temperature of the microorganisms is in the range of 10-20°C. The culturing pH value of the microorganisms is in the range of 5.7-11.0. The microorganisms are cultured with one or more carbon sources selected from a group including fructose, galactose, soluble starch, inositol, glycerol, dextrose, lactose, dextrin, adonitol, manitol, mannose, maltose, raffinose, and ethanol. The microorganisms are cultured with one or more organic nitrogen sources selected from a group including peptone, soytone, casamino acids, tryptone, yeast extracts, and malt extracts.
Biological: Coronavac Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
The invention discloses an external traditional Chinese medicine prescription capable of dispelling phlegm, removing dampness, activating blood circulation to removing stasis, eliminating swelling, and relieving pains. The prescription is composed of castor seed, Chinese angelica, rheum officinale, rehmanniae radix, bitter orange, phellodendron, Peking euphorbia, cassia bark, dahurian angelica root, notopterygium root, cyperus rotundus, peach seed, asarum herb, Chinese gall, pangolin, angelica pubescens, radix scrophulariae, saposhnicovia divaricata, coptis, curcuma rhizome, centipede, and litharge. The components are compounded according to the traditional Chinese medicine dialectic theory. The prescription can be pasted on the Weizhong acupoint and Ashi acupoint to treat the waist diseases; on the Jianjing acupoints and Ashi acupoint to treat cervical spondylosis; on the Shenque acupoint (navel) to treat dysmenorrheal; on the Yongquan acupoint to treat dry cough; on the Danzhong acupoint and Zhiyang acupoint to treat infection of respiratory tracts and lung; and on the Danzhong acupoint and Tiantu acupoint to treat throat inflammation. The prescription can be made into pills to treat hemorrhoids. The provided prescription has the advantages of reasonable formula, prominent effect, little side and toxic effect, proper price, and user-friendliness, and can be used to treat many chronic diseases in clinic.
Clonidine hydrochloride extended-release is a centrally acting alpha2-adrenergic agonist available as 0.1 mg extended-release tablets for oral administration. Each 0.1 mg tablet is equivalent to 0.087 mg of the free base.

The inactive ingredients are povidone, sodium lauryl sulfate, lactose monohydrate, microcrystalline cellulose, hypromellose, colloidal silicon dioxide and magnesium stearate. The formulation is designed to delay the absorption of active drug in order to decrease peak to trough plasma concentration differences. Clonidine hydrochloride is an imidazoline derivative and exists as a mesomeric compound. The chemical name is 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride. The following is the structural formula:

Clonidine hydrochloride is an odorless, bitter, white, crystalline substance soluble in water and alcohol.